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Aim: Negative symptoms are associated with poor outcome in patients with schizophrenia but are 
generally resistant to treatment. There has been growing interest in the role of negative symptoms in the 
early stages of the illness. In this study, we examine the association between negative symptoms in 
patients at initial presentation with first episode psychosis and clinical outcome at 1-year.  
Methods: Clinical data were utilized from five London Early Intervention Services included in the 
MiData audit database. The sample comprised 484 first-episode psychosis patients with complete Positive 
and Negative Syndrome Scale data at baseline and 1-year follow-up. Multiple imputation (N = 50) was 
conducted to account for missing follow-up data.  
Results: Baseline negative symptoms were associated with male gender (B = -1.63, p <. 05), younger age 
of onset (B = -.15, p <. 05), a higher level of impairment on the Global Assessment of Functioning 
(disability) scale at baseline (B = -.19, p <. 010), an absence of reported substance misuse prior to 
baseline assessment (B = -3.05, p <. 001), and unemployment at baseline (B = -.93, p <. 01). At 1-year 
follow-up, negative symptoms at presentation were associated with worse Global Assessment of 
Functioning symptom (B = -.28, p <.01) and disability (B = -.27, p <. 05) scales, and with hospital 
admission (OR= 1.06, p <.01). 
Conclusions: Negative symptoms at presentation to Early Intervention Services were associated with 
worse functioning at entry and poorer outcomes one year later. Future research is required to better 
understand the aetiology and trajectories of negative symptoms in early psychosis and propose novel 
targeted interventions. 
 




Negative symptoms (NS) remain an unmet therapeutic need for people suffering from psychosis 
(Chue & Lalonde, 2014; Kirkpatrick, 2014). In first-episode psychosis (FEP) studies NS at onset have 
been related to poor social functioning after the first year of treatment and at 2 and even 7 years after first 
presentation to services (Ayesa-Arriola et al., 2013; Best, Grossman, Oyewumi, & Bowie, 2014; Milev, 
Ho, Arndt, & Andreasen, 2005). Moreover, Best and colleagues (2014) indicated NS as the best 
symptomatic predictor of functioning both cross-sectionally and longitudinally in a FEP sample, in 
keeping with other early psychosis (Cacciotti-Saija, Langdon, Ward, Hickie, & Guastella, 2016) and 
mixed chronicity (Hunter & Barry, 2012; Rabinowitz et al., 2012) studies. Research has also linked NS 
with symptomatic outcomes and recovery after a FEP. Among other variables, NS were reported as 
predictors of a continuous illness course at 5-year follow-up (Bertelsen et al., 2008) and were associated 
with a lower likelihood of achieving recovery (Gee et al., 2016; Novick, Haro, Suarez, Vieta, & Naber, 
2009; Schubert, Clark, & Baune, 2015) and clinical remission (Díaz et al., 2013; Gaebel et al., 2014; 
Levine & Leucht, 2013; Üçok, Serbest, & Kandemir, 2011; Verma, Subramaniam, Abdin, Poon, & 
Chong, 2012). 
Although evidence for the role of negative symptoms in predicting outcome in first episode psychosis 
is growing, there are relatively few studies at present that investigate this association in real world clinical 
settings. In this naturalistic study, we investigate the relationship between negative symptoms in patients 
presenting to specialist Early Intervention Services (EIS) in London to baseline socio-demographic and 






This study was a naturalistic cohort of consecutive referrals to seven London EIS in the UK, assessed 
within one month of entry and followed up after one year. The teams were based in the following 
National Health Service (NHS) Mental Health Trusts: Camden and Islington (C&I EIS); South London 
and Maudsley (Lewisham EIS & STEP); East London and the City (EQUIP); Central and North West 
London (Brent and Kensington, Chelsea & Westminster EIS) and South West London and St. George’s 
(ETHOS).  
The patient inclusion criteria for EIS services were: (i) aged between 14 and 35 years old, (ii) 
presenting to the EIS for the first time with a psychotic episode lasting at least 7 days, and (iii) resident 
within the EIS catchment area (Fisher et al., 2008).  Patients with psychotic symptoms due to acute drug 
intoxication were excluded. 
Data were collected using the MiData audit tool, a standardized computerised assessment package of 
a minimum set of assessments used in routine clinical practice in EIS. Assessment measures were 
completed by trained clinicians as part of their routine assessments within 1 month of entry to the EIS 
(baseline) and at 1 year (follow-up) (Fisher et al., 2008). 
Assessment measures. 
Socio-demographic information. Basic demographic data were obtained at baseline, including 
gender, age at onset of psychosis, employment status, ethnicity based on the 2001 UK national census 
categories, degree of social support (‘good’, ‘limited’ or ‘none’), and the presence or absence of a history 
of psychosis in a first-degree relative.  
Clinical measures. At baseline, duration of untreated psychosis (DUP) was assessed with a 
revised version of the Nottingham Onset Schedule (Singh et al., 2005). The following measures were 
completed at both entry to the service and after 1 year in contact with the service: the Positive and 
Negative Syndrome Scale (PANSS) (Kay, Fiszbein, & Opler, 1987) including positive (PANSS-P), 
negative (PANSS-N) and general (PANSS-G) subscales; the Global Assessment of Functioning Scale for 
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symptoms (GAF-s) and disability (GAF-d) (Endicott, Spitzer, Fleiss, & Cohen, 1976); and the Combined 
Alcohol and Drug Use Scale (Drake & Wallach, 1989). International Classification of Diseases 10th 
edition (ICD-10) (World Health Organization, 1993) diagnosis was recorded at 1-year follow-up and was 
extracted from clinical records and confirmed with EIS consultant psychiatrists. Diagnoses were grouped 
into schizophrenia-spectrum disorders (ICD-10 codes F20-29), affective psychoses (F30.2, F31.2, F31.5, 
F32.3, F33.3 or F39), and other disorders (all other codes).  
During the 1-year follow-up period, the occurrence of psychiatric admission to an in-patient 
ward, the use of a crisis or Home Treatment team (HTT), and the occurrence of any suicide attempts or of 
any violent incidents was determined from the clinical records. Adherence to treatment was ascertained 
using the treatment adherence subscale of the Service Engagement Scale (Tait, Birchwood, & Trower, 
2002), scored on a 4-point Likert-type scale, with higher scores reflecting patients’ greater levels of non-
compliance. 
Two new composite variables were created. PANSS–D yielded presence of depression at baseline 
when patients had a score greater than 3 for all the following PANSS-G items: somatic concerns (G1), 
anxiety (G2), guilty feelings (G3) and depression (G6) (Kay & Sevy, 1990; Kjelby, Jørgensen, Kroken, 
Løberg, & Johnsen, 2011). This measure was created to ensure that the NS explored were not secondary 
to depression. Based on follow-up PANSS data, overall symptomatic Remission was defined as scores ≤3 
on all of the following PANSS items: delusions (P1), unusual thought content (G9), hallucinations (P3), 
conceptual disorganization (P2), mannerisms and posturing (G5), blunted affect (N1), social withdrawal 
(N4), and lack of spontaneity (N6). Overall symptomatic Remission was also calculated at baseline, using 
PANSS baseline data. Positive Symptom Remission was defined as scores ≤3 for the P1, P2, and P3 items 





Preliminary analysis  
Normality and outliers testing was carried out for all continuous variables used in the analysis. 
Collinearity between independent variables was tested for with the variance inflation factor (VIF) (Field, 
2009). Missing values were imputed using Multiple Imputation (MI) creating 50 imputed data sets.(See 
the Supplementary materials A, B and C for further details). 
Main analyses 
Hierarchical linear regression was conducted to explore associations with socio-demographic or key 
baseline clinical variables and baseline NS, with PANSS-N being the dependent variable. To investigate 
the relationship of baseline PANSS-N with outcomes at 1-year, multiple linear regressions and binomial 
logistic regressions were carried out for continuous and categorical outcome variables respectively, using 
baseline PANSS-N as the predictor in each case. Associations were then adjusted for relevant clinical and 
demographic covariates, namely ethnicity, social support at baseline, family history of psychosis, gender, 
age at onset, employment status at baseline, DUP, clinical diagnosis at 1-year follow-up, adherence to 
medication, and substance abuse or dependence 6 months prior to baseline assessment. PANSS-D, 
PANSS-P and Remission status at baseline were included as covariates to control for depression and 
severity of psychotic symptoms at baseline. Lastly, since the data were drawn from different EIS across 
London, team allocation was also included as a covariate in the adjusted model. All analyses were carried 
out using SPSS version 22 (IBM). 
Ethical Approval 
Data collection by each EIS was conducted in accordance with local audit procedures, which do not 
require patient consent. Any information that could lead to patient identification was removed. Multi-
centre ethical approval was obtained from the Wandsworth Research Ethics Committee, which granted 
permission for secondary research use of the data for a specific set of research questions, including NS 




Sample characteristics at baseline assessment  
Socio-demographic and clinical characteristics of the sample (N = 484) are summarised in Table 1. 
Both pooled estimates from the 50 imputed datasets and the original dataset are presented. This sample 
comprised 315 males (61.5%) and the mean age of psychosis onset was 22.9 years (SD = 5.12).  
Baseline Negative Symptoms and characteristics at presentation to EIS 
An exploratory forced entry hierarchical linear regression analysis revealed a significant association 
between baseline PANSS-N score and gender, age of onset, substance use in the preceding 6 months, 
occupation status and GAF-d score (R2 =.31, F (21, 462) = 12.75, p < .001; Table 2). Female participants 
had lower PANSS-N scores at baseline than males (p = .020); those with any substance use in the past 6 
months before baseline assessment had lower PANSS-N than those that had not used (p <.001); 
participants that were employed or in education at baseline scored lower on PANSS-N than those who 
were unemployed (p = .014); those with more impaired functioning had higher NS (p < .001); and 
younger age of onset was also associated with higher PANSS-N scores (p = .035). Post-hoc analysis of 
the relationship between PANSS-N at baseline and individual substance use including opioid, 
cannabinoid, alcohol, nicotine, cocaine and stimulant use in the model, revealed that only cannabinoid 
abuse or dependence was associated with lower PANSS-N scores (B = -2.17, B SE = .94, t = -2.39, 95% 
CI -4.01 – -.33, p =.021; Supplementary Materials D).  
Baseline NS and clinical outcomes at 1-year follow-up 
PANSS-N at baseline was significantly associated with worse symptoms (GAF-s; B = -.28, p =.007) 
and impaired functioning (GAF-d; B = -.21, p = .01) at 1-year follow-up (Table 3). PANSS-N at baseline 
was also associated with higher likelihood of patients being admitted to a psychiatric ward during 1-year 
follow-up, with one point increase in PANSS-N increasing the odds of being admitted during 1-year 
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follow-up by 6%, (OR = 1.06, 95% CI 1.03 – 1.10, Wald statistic = 14.77, p =.001; Table 4). The mean 
(SD) PANSS-N of those who were admitted (N = 206) was 18.70 (9.47) compared to 14.99 (7.34) for 
those who were not admitted (N = 278). However, no significant associations were found between NS at 
baseline and Remission of symptoms at 1-year follow-up, nor with risk behaviors or use of HTT or Crisis 
teams during this period. 
Discussion 
Negative symptoms: baseline correlates 
Participants with higher levels of baseline NS were much more likely to be male, in accordance with 
previous literature in both cross-sectional (Drake et al., 2016; Thorup et al., 2007) and follow-up FEP 
studies (Stone et al., 2014; Thorup et al., 2014). Although earlier investigations of gender-specific 
patterns of negative psychopathology have been contradictory (Ochoa, Usall, Cobo, Labad, & Kulkarni, 
2012), most early psychosis studies are consistent with our findings (Köhler et al., 2009; Køster, Lajer, 
Lindhardt, & Rosenbaum, 2008; Thorup et al., 2014; Thorup et al., 2007; Willhite et al., 2008),  including 
studies of individuals at-risk for psychosis (Rietschel et al., 2015). In our study, severity of  baseline NS 
was related to a younger age of psychosis onset, which is consistent with most (Ballageer, Malla, 
Manchanda, Takhar, & Haricharan, 2005; Dominguez, Saka, Lieb, Wittchen, & van Os, 2010; Drake et 
al., 2016; Üçok & Ergül, 2014), but not all (Schultz et al., 1997), previous findings.  
We found that patients with a higher level of NS had worse social and vocational functioning at 
entry to EIS. This is in keeping with previous work in FEP patients by Best et al.(Best et al., 2014). Poor 
premorbid functioning in those with prominent levels of NS at first presentation with psychosis could 
explain the poor social functioning found at baseline (Chang et al., 2016). Thus, patients with NS might 
have already suffered functional deterioration during the prodromal phase of psychosis (Corcoran et al., 
2011; Kim et al., 2013; Meyer et al., 2014). 
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We found that substance abuse or dependence in the 6-month period preceding entry to EIS was 
associated with lower levels of NS at presentation. Although there is a lack of FEP research on this 
relationship, existing studies are conflicting, with some being in agreement with the present result (J. 
Addington & Addington, 1998) and others finding no difference in NS symptoms between substance 
users and non-users (Sevy et al., 2008). In a post-hoc analyses, only abuse of cannabinoids emerged as a 
significant association with lower baseline NS levels, accounting for other recent substance abuse 
(opioids, alcohol, nicotine, stimulants, cocaine). It has been suggested that those experiencing a FEP may 
use cannabis to self-medicate (Khantzian, 1997), possibly alleviating some NS such as anhedonia (Gregg, 
Barrowclough, & Haddock, 2007; Potvin, Sepehry, & Stip, 2005; Simon, Belzeaux, Adida, & Azorin, 
2015), or higher NS could imply less hedonic capacity which in turn could reduce drug-seeking 
(Compton, Whicker, & Hochman, 2007). Another possible explanation is that those with less severe NS 
use more cannabis due to better functioning, i.e. are more capable of obtaining substances or more prone 
to substance abuse, as it has been indicated that FEP patients with cannabis abuse disorder show a 
stronger premorbid social functioning (Carr et al., 2009; Potvin et al., 2005). Nevertheless, there is still 
paucity of research, especially in FEP and more research is needed to clarify this association (Seddon et 
al., 2016; Simon et al., 2015). 
Negative symptoms: clinical and functional outcomes 
Baseline NS were related to higher possibility of admission to a psychiatric ward, used as a proxy 
of deterioration or relapse (Addington, Patten, McKenzie, & Addington, 2013). Previous studies generally 
support this finding (Morgan, Korten, & Jablensky, 2006; Patel et al., 2015; Sipos, 2001), although one 
study did not replicate this finding (Addington et al., 2010). We found baseline NS were also associated 
with worse symptoms at 1-year follow-up, as reflected in GAF-s and did not predict symptomatic 
remission at follow-up, being in accordance with previous studies (Cesková, Radovan, Tomás, & Hana, 
2007)(Chang et al., 2012).  
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Risk behaviours, i.e. suicidality and violence incidents, were not predicted by NS levels. Our 
results are consistent with another FEP study that failed to find an association between NS and suicide 
attempts (Bertelsen et al., 2007) and  studies that have linked mainly positive (Foley et al., 2007; Winsper 
et al., 2013) or manic symptoms (Dean et al., 2007; Large & Nielssen, 2011) to violent behavior during 
FEP.  
Higher NS at baseline were associated with worse functioning at 1-year follow-up as reflected by 
the GAF-d scores. This finding is consistent with most FEP studies to date that show NS as a critical 
determinant of both global and social functioning (Cacciotti-Saija et al., 2016) as well as real-world 
functioning (Robertson et al., 2014), for at least 2 years after the FEP (Bergé et al., 2016).  Recent 
research has supported this link at the at-risk for psychosis stage as well (Meyer et al., 2014). Thus, it 
could be that those with high negative symptoms at presentation, even when these symptoms decrease, 
are less likely to achieve recovery, which could be explained by highly disrupted premorbid functioning 
(Gee et al., 2016). 
Strengths and limitations 
This study has several strengths. The FEP sample was large, naturalistic, from different EIS within 
well-defined catchment areas, with minimal confounding effects of chronicity, institutionalization and 
prolonged exposure to antipsychotic treatment. Previous studies have indicated that FEP patients with 
higher NS might be at greater risk of dropping out (AlAqeel & Margolese, 2012; Thompson et al., 2011; 
Üçok & Ergül, 2014). Thus, although there was a considerable amount of missing data due to the 
naturalistic follow-up study design, MI was applied in order to correct for biases due to non-completion 
(Schafer & Graham, 2002). The differences between the original dataset and the pooled estimates showed 
that MI considered that those with missing follow-up data might have had high NS scores.  
Nonetheless, a few caveats need to be considered. Firstly, due to the design of this study, some ethnic 
minorities and clinical subgroups might have been over/under-represented, which potentially limits the 
10 
 
generalizability of the findings. Patients with lower severity of positive symptoms were more likely to 
have a fully completed PANSS at baseline, leading to over-representation of cases with lower positive 
symptoms. However, their mean difference was less than 3 points, possibly not representing a clinically 
significant difference. Additionally, cross-sectional remission rate estimation at baseline and follow-up 
tends to be more vulnerable to confounding variables and lacks specificity. Lastly, regarding controlling 
for secondary NS, although this study controlled for positive symptoms and depression, it did not take 
into account extra-pyramidal side-effects (EPS) since there was no measure available (Millan et al., 
2014). 
Clinical implications 
The present findings suggest that NS are associated poorer global functioning and symptomatic 
outcomes and increased likelihood of admission, leading to several clinical implications. This is 
noteworthy since social and occupational functioning have been indicated as the most important recovery 
markers by both field experts (Kane et al., 2003) and experts by lived experience (Pitt, Kilbride, Nothard, 
Welford, & Morrison, 2007).  Based on the relative fluctuation of NS in FEP and their increasing stability 
after the first year (Chang et al., 2011; Ventura et al., 2015), this period might be a therapeutic window to 
ameliorate negative symptomatology, prevent disability and maximize functional outcome. Further 
investigations should examine the prognostic significance of timely, intensive and integrated intervention 
in NS during this potential critical period in preventing emergence of persistence. Careful monitoring of 
those showing higher NS at presentation warrants the attention of EIS ( Gee et al., 2016), if possible from 
the at-risk stage of the illness when NS often occur (Fusar-Poli et al., 2013). While emphasizing the need 
for specific treatment approaches for reducing the burden of NS (Schennach-Wolff et al., 2011; Verdoux 
et al., 2001), it might be important to distinguish between primary NS and secondary NS, as the latter can 




Negative symptoms in FEP are a significant problem, leading to worse functional and clinical 
outcomes even amongst patients treated by specialist services. Since pharmacological treatments (Fusar-
Poli et al., 2015) and psychosocial interventions (Jauhar et al., 2014; Østergaard Christensen et al., 2014) 
have shown to have little or no effect, further studies are needed in order to tackle NS, early and 





Addington, D. E., Beck, C., Wang, J., Adams, B., Pryce, C., Zhu, H., … McKenzie, E. (2010). Predictors 
of admission in first-episode psychosis: developing a risk adjustment model for service 
comparisons. Psychiatric Services (Washington, D.C.), 61(5), 483–488. 
https://doi.org/10.1176/appi.ps.61.5.483 
Addington, D. E., Patten, S. B., McKenzie, E., & Addington, J. (2013). Relationship Between Relapse 
and Hospitalization in First-Episode Psychosis. Psychiatric Services, 64(8), 796–799. 
https://doi.org/10.1176/appi.ps.201200440 
Addington, J., & Addington, D. (1998). Effect of substance misuse in early psychosis. The British 
Journal of Psychiatry. Supplement, 172(33), 134–136. 
AlAqeel, B., & Margolese, H. C. (2012). Remission in schizophrenia: critical and systematic review. 
Harvard Review of Psychiatry, 20(6), 281–297. https://doi.org/10.3109/10673229.2012.747804 
Albert, N., Bertelsen, M., Thorup, A., Petersen, L., Jeppesen, P., Le Quack, P., … Nordentoft, M. (2011). 




Andreasen, N. C., Carpenter, W. T., Kane, J. M., Lasser, R. A., Marder, S. R., & Weinberger, D. R. 
(2005). Remission in schizophrenia: proposed criteria and rationale for consensus. The American 
Journal of Psychiatry, 162(3), 441–449. https://doi.org/10.1176/appi.ajp.162.3.441 
Ayesa-Arriola, R., Manuel Rodríguez-Sánchez, J., Pérez-Iglesias, R., González-Blanch, C., Pardo-García, 
G., Tabares-Seisdedos, R., … Crespo-Facorro, B. (2013). The relevance of cognitive, clinical and 
premorbid variables in predicting functional outcome for individuals with first-episode psychosis: 
A 3 year longitudinal study. Psychiatry Research, 209(3), 302–308. 
https://doi.org/10.1016/j.psychres.2013.01.024 
Ballageer, T., Malla, A., Manchanda, R., Takhar, J., & Haricharan, R. (2005). Is adolescent-onset first-
episode psychosis different from adult onset? Journal of the American Academy of Child and 
Adolescent Psychiatry, 44(8), 782–789. https://doi.org/10.1097/01.chi.0000164591.55942.ea 
Bergé, D., Mané, A., Salgado, P., Cortizo, R., Garnier, C., Gomez, L., … Pérez, V. (2016). Predictors of 
Relapse and Functioning in First-Episode Psychosis: A Two-Year Follow-Up Study. Psychiatric 
Services, 67(2), 227–233. https://doi.org/10.1176/appi.ps.201400316 
Bertelsen, M., Jeppesen, P., Petersen, L., Thorup, A., OHLENSCHLAeGER, J., Quach, P. L., … 
Nordentoft, M. (2007). Suicidal behaviour and mortality in first-episode psychosis: the OPUS 
trial. The British Journal of Psychiatry, 191(51), s140–s146. 
https://doi.org/10.1192/bjp.191.51.s140 
Bertelsen, M., Jeppesen, P., Petersen, L., Thorup, A., Øhlenschlaeger, J., le Quach, P., … Nordentoft, M. 
(2008). Five-year follow-up of a randomized multicenter trial of intensive early intervention vs 
standard treatment for patients with a first episode of psychotic illness: the OPUS trial. Archives 
of General Psychiatry, 65(7), 762–771. https://doi.org/10.1001/archpsyc.65.7.762 
Best, M. W., Grossman, M., Oyewumi, L. K., & Bowie, C. R. (2014). Examination of the Positive and 
Negative Syndrome Scale factor structure and longitudinal relationships with functioning in early 




Cacciotti-Saija, C., Langdon, R., Ward, P. B., Hickie, I. B., & Guastella, A. J. (2016). Clinical symptoms 
predict concurrent social and global functioning in an early psychosis sample: Clinical symptoms 
predict functioning in early psychosis. Early Intervention in Psychiatry, n/a-n/a. 
https://doi.org/10.1111/eip.12295 
Carbon, M., & Correll, C. U. (2014). Thinking and acting beyond the positive: the role of the cognitive 
and negative symptoms in schizophrenia. CNS Spectrums, 19(S1), 35–53. 
https://doi.org/10.1017/S1092852914000601 
Carr, J. A. R., Norman, R. G. M., & Manchanda, R. (2009). Sociodemographic and clinical characteristics 
of patients presenting with first-episode psychosis and concurrent substance misuse. Early 
Intervention in Psychiatry, 3(1), 75–79. https://doi.org/10.1111/j.1751-7893.2008.00100.x 
Cesková, E., Radovan, P., Tomás, K., & Hana, K. (2007). One-year follow-up of patients with first-
episode schizophrenia (comparison between remitters and non-remitters). Neuropsychiatric 
Disease and Treatment, 3(1), 153–160. 
Chang, W. C., Hui, C. L. M., Tang, J. Y. M., Wong, G. H. Y., Lam, M. M. L., Chan, S. K. W., & Chen, 
E. Y. H. (2011). Persistent negative symptoms in first-episode schizophrenia: a prospective three-
year follow-up study. Schizophrenia Research, 133(1–3), 22–28. 
https://doi.org/10.1016/j.schres.2011.09.006 
Chang, W. C., Tang, J. Y., Hui, C. L., Lam, M. M., Chan, S. K., Wong, G. H., … Chen, E. Y. (2012). 
Prediction of remission and recovery in young people presenting with first-episode psychosis in 
Hong Kong: A 3-year follow-up study. Australian and New Zealand Journal of Psychiatry, 46(2), 
100–108. https://doi.org/10.1177/0004867411428015 
Chang, W. C., Lau, C. F. C., Chan, S. S. I., Hui, C. L. M., Chan, S. K. W., Lee, E. H. M., … Chen, E. Y. 
H. (2016). Premorbid, clinical and cognitive correlates of primary negative symptoms in first-




Chue, P., & Lalonde, J. (2014). Addressing the unmet needs of patients with persistent negative 
symptoms of schizophrenia: emerging pharmacological treatment options. Neuropsychiatric 
Disease and Treatment, 777. https://doi.org/10.2147/NDT.S43404 
Compton, M. T., Whicker, N. E., & Hochman, K. M. (2007). Alcohol and cannabis use in Urban, African 
American, first-episode schizophrenia-spectrum patients: associations with positive and negative 
symptoms. The Journal of Clinical Psychiatry, 68(12), 1939–1945. 
Corcoran, C. M., Kimhy, D., Parrilla-Escobar, M. A., Cressman, V. L., Stanford, A. D., Thompson, J., … 
Malaspina, D. (2011). The relationship of social function to depressive and negative symptoms in 
individuals at clinical high risk for psychosis. Psychological Medicine, 41(02), 251–261. 
https://doi.org/10.1017/S0033291710000802 
Dean, K., Walsh, E., Morgan, C., Demjaha, A., Dazzan, P., Morgan, K., … Murray, R. M. (2007). 
Aggressive behaviour at first contact with services: findings from the AESOP First Episode 
Psychosis Study. Psychological Medicine, 37(04), 547–557. 
https://doi.org/10.1017/S0033291706008920 
Díaz, I., Pelayo-Terán, J. M., Pérez-Iglesias, R., Mata, I., Tabarés-Seisdedos, R., Suárez-Pinilla, P., … 
Crespo-Facorro, B. (2013). Predictors of clinical remission following a first episode of non-
affective psychosis: Sociodemographics, premorbid and clinical variables. Psychiatry Research, 
206(2–3), 181–187. https://doi.org/10.1016/j.psychres.2012.10.011 
Dominguez, M.-G., Saka, M. C., Lieb, R., Wittchen, H.-U., & van Os, J. (2010). Early Expression of 
Negative/Disorganized Symptoms Predicting Psychotic Experiences and Subsequent Clinical 
Psychosis: A 10-Year Study. American Journal of Psychiatry, 167(9), 1075–1082. 
https://doi.org/10.1176/appi.ajp.2010.09060883 
Drake, R. E., & Wallach, M. A. (1989). Substance abuse among the chronic mentally ill. Hospital & 
Community Psychiatry, 40(10), 1041–1046. 
15 
 
Drake, R. J., Addington, J., Viswanathan, A. C., Lewis, S. W., Cotter, J., Yung, A. R., & Abel, K. M. 
(2016). How Age and Gender Predict Illness Course in a First-Episode Nonaffective Psychosis 
Cohort. The Journal of Clinical Psychiatry, e283–e289. https://doi.org/10.4088/JCP.14m09369 
Endicott, J., Spitzer, R. L., Fleiss, J. L., & Cohen, J. (1976). The global assessment scale. A procedure for 
measuring overall severity of psychiatric disturbance. Archives of General Psychiatry, 33(6), 
766–771. 
Field, A. P. (2009). Discovering statistics using SPSS: (and sex, drugs and rock “n” roll) (3rd ed). Los 
Angeles: SAGE Publications. 
Fisher, H., Theodore, K., Power, P., Chisholm, B., Fuller, J., Marlowe, K., … Johnson, S. (2008). Routine 
evaluation in first episode psychosis services: feasibility and results from the MiData project. 
Social Psychiatry and Psychiatric Epidemiology, 43(12), 960–967. 
https://doi.org/10.1007/s00127-008-0386-1 
Foley, S. R., Browne, S., Clarke, M., Kinsella, A., Larkin, C., & O’Callaghan, E. (2007). Is violence at 
presentation by patients with first-episode psychosis associated with duration of untreated 
psychosis? Social Psychiatry and Psychiatric Epidemiology, 42(8), 606–610. 
https://doi.org/10.1007/s00127-007-0217-9 
Fusar-Poli, P., Borgwardt, S., Bechdolf, A., Addington, J., Riecher-Rössler, A., Schultze-Lutter, F., … 
Yung, A. (2013). The Psychosis High-Risk State: A Comprehensive State-of-the-Art Review. 
JAMA Psychiatry, 70(1), 107. https://doi.org/10.1001/jamapsychiatry.2013.269 
Fusar-Poli, P., Papanastasiou, E., Stahl, D., Rocchetti, M., Carpenter, W., Shergill, S., & McGuire, P. 
(2015). Treatments of Negative Symptoms in Schizophrenia: Meta-Analysis of 168 Randomized 
Placebo-Controlled Trials. Schizophrenia Bulletin, 41(4), 892–899. 
https://doi.org/10.1093/schbul/sbu170 
Gaebel, W., Riesbeck, M., Wölwer, W., Klimke, A., Eickhoff, M., von Wilmsdorff, M., … Möller, H.-J. 
(2014). Rates and predictors of remission in first-episode schizophrenia within 1year of 
antipsychotic maintenance treatment. Results of a randomized controlled trial within the German 
16 
 
Research Network on Schizophrenia. Schizophrenia Research, 152(2–3), 478–486. 
https://doi.org/10.1016/j.schres.2013.04.012 
Gee, B., Hodgekins, J., Fowler, D., Marshall, M., Everard, L., Lester, H., … Birchwood, M. (2016). The 
course of negative symptom in first episode psychosis and the relationship with social recovery. 
Schizophrenia Research, 174(1–3), 165–171. https://doi.org/10.1016/j.schres.2016.04.017 
Gregg, L., Barrowclough, C., & Haddock, G. (2007). Reasons for increased substance use in psychosis. 
Clinical Psychology Review, 27(4), 494–510. https://doi.org/10.1016/j.cpr.2006.09.004 
Hadden, K. L., LeDrew, K., Hogan, K., & Thomas, B. (2016). Impact of comorbid cannabis use on 
outcome in first episode psychosis: Cannabis use in first-episode psychosis. Early Intervention in 
Psychiatry. https://doi.org/10.1111/eip.12377 
Hafner, H., Maurer, K., Loffler, W., & Riecher-Rossler, A. (1993). The influence of age and sex on the 
onset and early course of schizophrenia. The British Journal of Psychiatry, 162(1), 80–86. 
https://doi.org/10.1192/bjp.162.1.80 
Harvey, P. D., Koren, D., Reichenberg, A., & Bowie, C. R. (2006). Negative Symptoms and Cognitive 
Deficits: What Is the Nature of Their Relationship? Schizophrenia Bulletin, 32(2), 250–258. 
https://doi.org/10.1093/schbul/sbj011 
Hunter, R., & Barry, S. (2012). Negative symptoms and psychosocial functioning in schizophrenia: 
Neglected but important targets for treatment. European Psychiatry, 27(6), 432–436. 
https://doi.org/10.1016/j.eurpsy.2011.02.015 
Jauhar, S., McKenna, P. J., Radua, J., Fung, E., Salvador, R., & Laws, K. R. (2014). Cognitive-
behavioural therapy for the symptoms of schizophrenia: systematic review and meta-analysis 
with examination of potential bias. The British Journal of Psychiatry, 204(1), 20–29. 
https://doi.org/10.1192/bjp.bp.112.116285 
Kane, J. M., Leucht, S., Carpenter, D., Docherty, J. P., & Expert Consensus Panel for Optimizing 
Pharmacologic Treatment of Psychotic Disorders. (2003). The expert consensus guideline series. 
17 
 
Optimizing pharmacologic treatment of psychotic disorders. Introduction: methods, commentary, 
and summary. The Journal of Clinical Psychiatry, 64 Suppl 12, 5–19. 
Kay, S. R., Fiszbein, A., & Opler, L. A. (1987). The positive and negative syndrome scale (PANSS) for 
schizophrenia. Schizophrenia Bulletin, 13(2), 261–276. 
Kay, S. R., & Sevy, S. (1990). Pyramidical Model of Schizophrenia. Schizophrenia Bulletin, 16(3), 537–
545. https://doi.org/10.1093/schbul/16.3.537 
Khantzian, E. J. (1997). The Self-Medication Hypothesis of Substance Use Disorders: A Reconsideration 
and Recent Applications. Harvard Review of Psychiatry, 4(5), 231–244. 
https://doi.org/10.3109/10673229709030550 
Kim, K. R., Song, Y. Y., Park, J. Y., Lee, E. H., Lee, M., Lee, S. Y., … Kwon, J. S. (2013). The 
relationship between psychosocial functioning and resilience and negative symptoms in 
individuals at ultra-high risk for psychosis. Australian & New Zealand Journal of Psychiatry, 
47(8), 762–771. https://doi.org/10.1177/0004867413488218 
Kirkpatrick, B. (2014). Progress in the Study of Negative Symptoms. Schizophrenia Bulletin, 40(Suppl 
2), S101–S106. https://doi.org/10.1093/schbul/sbt158 
Kjelby, E., Jørgensen, H. A., Kroken, R. A., Løberg, E.-M., & Johnsen, E. (2011). Anti-depressive 
effectiveness of olanzapine, quetiapine, risperidone and ziprasidone: a pragmatic, randomized 
trial. BMC Psychiatry, 11(1). https://doi.org/10.1186/1471-244X-11-145 
Köhler, S., van der Werf, M., Hart, B., Morrison, G., McCreadie, R., Kirkpatrick, B., … Allardyce, J. 
(2009). Evidence that better outcome of psychosis in women is reversed with increasing age of 
onset: A population-based 5-year follow-up study. Schizophrenia Research, 113(2–3), 226–232. 
https://doi.org/10.1016/j.schres.2009.05.017 
Køster, A., Lajer, M., Lindhardt, A., & Rosenbaum, B. (2008). Gender differences in first episode 




Large, M. M., & Nielssen, O. (2011). Violence in first-episode psychosis: A systematic review and meta-
analysis. Schizophrenia Research, 125(2–3), 209–220. 
https://doi.org/10.1016/j.schres.2010.11.026 
Levine, S. Z., & Leucht, S. (2013). Attaining and sustaining remission of predominant negative 
symptoms. Schizophrenia Research, 143(1), 60–64. https://doi.org/10.1016/j.schres.2012.11.010 
Mané, A., Fernández-Expósito, M., Bergé, D., Gómez-Pérez, L., Sabaté, A., Toll, A., … Perez, V. (2015). 
Relationship between cannabis and psychosis: Reasons for use and associated clinical variables. 
Psychiatry Research, 229(1–2), 70–74. https://doi.org/10.1016/j.psychres.2015.07.070 
Meyer, E. C., Carrion, R. E., Cornblatt, B. A., Addington, J., Cadenhead, K. S., Cannon, T. D., … the 
NAPLS group. (2014). The Relationship of Neurocognition and Negative Symptoms to Social 
and Role Functioning Over Time in Individuals at Clinical High Risk in the First Phase of the 
North American Prodrome Longitudinal Study. Schizophrenia Bulletin, 40(6), 1452–1461. 
https://doi.org/10.1093/schbul/sbt235 
Milev, P., Ho, B.-C., Arndt, S., & Andreasen, N. C. (2005). Predictive Values of Neurocognition and 
Negative Symptoms on Functional Outcome in Schizophrenia: A Longitudinal First-Episode 
Study With 7-Year Follow-Up. American Journal of Psychiatry, 162(3), 495–506. 
https://doi.org/10.1176/appi.ajp.162.3.495 
Millan, M. J., Fone, K., Steckler, T., & Horan, W. P. (2014). Negative symptoms of schizophrenia: 
Clinical characteristics, pathophysiological substrates, experimental models and prospects for 
improved treatment. European Neuropsychopharmacology, 24(5), 645–692. 
https://doi.org/10.1016/j.euroneuro.2014.03.008 
Morgan, V., Korten, A., & Jablensky, A. (2006). Modifiable risk factors for hospitalization among people 
with psychosis: evidence from the National Study of Low Prevalence (Psychotic) Disorders. 




Novick, D., Haro, J. M., Suarez, D., Vieta, E., & Naber, D. (2009). Recovery in the outpatient setting: 36-
month results from the Schizophrenia Outpatients Health Outcomes (SOHO) study. 
Schizophrenia Research, 108(1–3), 223–230. https://doi.org/10.1016/j.schres.2008.11.007 
Ochoa, S., Usall, J., Cobo, J., Labad, X., & Kulkarni, J. (2012). Gender Differences in Schizophrenia and 
First-Episode Psychosis: A Comprehensive Literature Review. Schizophrenia Research and 
Treatment, 2012, 1–9. https://doi.org/10.1155/2012/916198 
Østergaard Christensen, T., Vesterager, L., Krarup, G., Olsen, B. B., Melau, M., Gluud, C., & Nordentoft, 
M. (2014). Cognitive remediation combined with an early intervention service in first episode 
psychosis. Acta Psychiatrica Scandinavica, 130(4), 300–310. https://doi.org/10.1111/acps.12287 
Patel, R., Jayatilleke, N., Broadbent, M., Chang, C.-K., Foskett, N., Gorrell, G., … Stewart, R. (2015). 
Negative symptoms in schizophrenia: a study in a large clinical sample of patients using a novel 
automated method. BMJ Open, 5(9), e007619. https://doi.org/10.1136/bmjopen-2015-007619 
Pitt, L., Kilbride, M., Nothard, S., Welford, M., & Morrison, A. P. (2007). Researching recovery from 
psychosis: a user-led project. Psychiatric Bulletin, 31(2), 55–60. 
https://doi.org/10.1192/pb.bp.105.008532 
Potvin, S., Sepehry, A. A., & Stip, E. (2005). A meta-analysis of negative symptoms in dual diagnosis 
schizophrenia. Psychological Medicine, 36(04), 431. 
https://doi.org/10.1017/S003329170500574X 
Rabinowitz, J., Levine, S. Z., Garibaldi, G., Bugarski-Kirola, D., Berardo, C. G., & Kapur, S. (2012). 
Negative symptoms have greater impact on functioning than positive symptoms in schizophrenia: 
Analysis of CATIE data. Schizophrenia Research, 137(1–3), 147–150. 
https://doi.org/10.1016/j.schres.2012.01.015 
Rietschel, L., Lambert, M., Karow, A., Zink, M., Müller, H., Heinz, A., … PREVENT study group. 
(2015). Clinical high risk for psychosis: gender differences in symptoms and social functioning: 




Robertson, B. R., Prestia, D., Twamley, E. W., Patterson, T. L., Bowie, C. R., & Harvey, P. D. (2014). 
Social competence versus negative symptoms as predictors of real world social functioning in 
schizophrenia. Schizophrenia Research, 160(1–3), 136–141. 
https://doi.org/10.1016/j.schres.2014.10.037 
Schafer, J. L., & Graham, J. W. (2002). Missing data: our view of the state of the art. Psychological 
Methods, 7(2), 147–177. 
Schennach-Wolff, R., Jäger, M., Mayr, A., Meyer, S., Kühn, K.-U., Klingberg, S., … Riedel, M. (2011). 
Predictors of response and remission in the acute treatment of first-episode schizophrenia patients 
— Is it all about early response? European Neuropsychopharmacology, 21(5), 370–378. 
https://doi.org/10.1016/j.euroneuro.2010.10.003 
Schubert, K. O., Clark, S. R., & Baune, B. T. (2015). The use of clinical and biological characteristics to 
predict outcome following First Episode Psychosis. Australian & New Zealand Journal of 
Psychiatry, 49(1), 24–35. https://doi.org/10.1177/0004867414560650 
Schultz, S. K., Miller, D. D., Oliver, S. E., Arndt, S., Flaum, M., & Andreasen, N. C. (1997). The life 
course of schizophrenia: age and symptom dimensions. Schizophrenia Research, 23(1), 15–23. 
https://doi.org/10.1016/S0920-9964(96)00087-4 
Seddon, J. L., Birchwood, M., Copello, A., Everard, L., Jones, P. B., Fowler, D., … Singh, S. P. (2016). 
Cannabis Use Is Associated With Increased Psychotic Symptoms and Poorer Psychosocial 
Functioning in First-Episode Psychosis: A Report From the UK National EDEN Study. 
Schizophrenia Bulletin, 42(3), 619–625. https://doi.org/10.1093/schbul/sbv154 
Sevy, S., Robinson, D. G., Holloway, S., Alvir, J. M., Woerner, M. G., Bilder, R., … Kane, J. (2008). 
Correlates of substance misuse in patients with first-episode schizophrenia and schizoaffective 
disorder: Substance misuse in schizophrenia. Acta Psychiatrica Scandinavica, 104(5), 367–374. 
https://doi.org/10.1111/j.1600-0447.2001.00452.x 
Simon, N., Belzeaux, R., Adida, M., & Azorin, J.-M. (2015). Symptômes négatifs dans la schizophrénie 
et addiction. L’Encéphale, 41(6), 6S27-6S31. https://doi.org/10.1016/S0013-7006(16)30007-0 
21 
 
Singh, S. P. (2010). Early intervention in psychosis. The British Journal of Psychiatry: The Journal of 
Mental Science, 196(5), 343–345. https://doi.org/10.1192/bjp.bp.109.075804 
Singh, S. P., Cooper, J. E., Fisher, H. L., Tarrant, C. J., Lloyd, T., Banjo, J., … Jones, P. (2005). 
Determining the chronology and components of psychosis onset: The Nottingham Onset 
Schedule (NOS). Schizophrenia Research, 80(1), 117–130. 
https://doi.org/10.1016/j.schres.2005.04.018 
Sipos, A. (2001). Patterns and predictors of hospitalisation in first-episode psychosis: Prospective cohort 
study. The British Journal of Psychiatry, 178(6), 518–523. https://doi.org/10.1192/bjp.178.6.518 
Stone, J. M., Fisher, H. L., Major, B., Chisholm, B., Woolley, J., Lawrence, J., … Young, A. H. (2014). 
Cannabis use and first-episode psychosis: relationship with manic and psychotic symptoms, and 
with age at presentation. Psychological Medicine, 44(03), 499–506. 
https://doi.org/10.1017/S0033291713000883 
Tait, L., Birchwood, M., & Trower, P. (2002). A new scale (SES) to measure engagement with 
community mental health services. Journal of Mental Health, 11(2), 191–198. 
https://doi.org/10.1080/09638230020023570-2 
Thompson, J., Berk, M., Dean, O., Kohlmann, K., Jeavons, S., Bush, A., & Copolov, D. (2011). Who’s 
left? Symptoms of schizophrenia that predict clinical trial dropout. Human Psychopharmacology, 
26(8), 609–613. https://doi.org/10.1002/hup.1253 
Thorup, A., Albert, N., Bertelsen, M., Petersen, L., Jeppesen, P., Le Quack, P., … Nordentoft, M. (2014). 
Gender differences in first-episode psychosis at 5-year follow-up – two different courses of 
disease? Results from the OPUS study at 5-year follow-up. European Psychiatry, 29(1), 44–51. 
https://doi.org/10.1016/j.eurpsy.2012.11.005 
Thorup, A., Petersen, L., Jeppesen, P., Ohlenschlaeger, J., Christensen, T., Krarup, G., … Nordentoft, M. 
(2007). Gender differences in young adults with first-episode schizophrenia spectrum disorders at 




Üçok, A., & Ergül, C. (2014). Persistent negative symptoms after first episode schizophrenia: A 2-year 
follow-up study. Schizophrenia Research, 158(1–3), 241–246. 
https://doi.org/10.1016/j.schres.2014.07.021 
Üçok, A., Serbest, S., & Kandemir, P. E. (2011). Remission after first-episode schizophrenia: Results of a 
long-term follow-up. Psychiatry Research, 189(1), 33–37. 
https://doi.org/10.1016/j.psychres.2010.11.013 
Ventura, J., Subotnik, K. L., Gitlin, M. J., Gretchen-Doorly, D., Ered, A., Villa, K. F., … Nuechterlein, K. 
H. (2015). Negative symptoms and functioning during the first year after a recent onset of 
schizophrenia and 8years later. Schizophrenia Research, 161(2–3), 407–413. 
https://doi.org/10.1016/j.schres.2014.10.043 
Verdoux, H., Liraud, F., Gonzales, B., Assens, F., Abalan, F., & van Os, J. (2001). Predictors and 
outcome characteristics associated with suicidal behaviour in early psychosis: a two-year follow-
up of first-admitted subjects. Acta Psychiatrica Scandinavica, 103(5), 347–354. 
https://doi.org/10.1034/j.1600-0447.2001.00202.x 
Verma, S., Subramaniam, M., Abdin, E., Poon, L. Y., & Chong, S. A. (2012). Symptomatic and 
functional remission in patients with first-episode psychosis: Remission in first-episode 
psychosis. Acta Psychiatrica Scandinavica, 126(4), 282–289. https://doi.org/10.1111/j.1600-
0447.2012.01883.x 
Willhite, R. K., Niendam, T. A., Bearden, C. E., Zinberg, J., O’Brien, M. P., & Cannon, T. D. (2008). 
Gender differences in symptoms, functioning and social support in patients at ultra-high risk for 
developing a psychotic disorder. Schizophrenia Research, 104(1–3), 237–245. 
https://doi.org/10.1016/j.schres.2008.05.019 
Winsper, C., Singh, S. P., Marwaha, S., Amos, T., Lester, H., Everard, L., … Birchwood, M. (2013). 
Pathways to Violent Behavior During First-Episode Psychosis: A Report From the UK National 
EDEN Study. JAMA Psychiatry, 70(12), 1287. https://doi.org/10.1001/jamapsychiatry.2013.2445 
23 
 
World Health Organization (Ed.). (1993). The ICD-10 classification of mental and behavioural disorders: 







Table 1. Socio-demographic and baseline clinical characteristics of the sample, for both pooled estimates 
from imputed data and original data 
Variable 
Pooled Original  
N (%) M (SD) N (%) M (Min-Max; SD) N of missing 
cases (%) 
Gender     0 
Male  315 (65.1)  315 (65.1)   
Female 169 (34.9)  169 (34.9)   
Ethnicity     0 
White British 96 (19.8)  96 (19.8)   
White Other  61 (12.6)  61 (12.6)   
Black 
Caribbean 
48 (9.9)  48 (9.9)   
Black African 126 (26.0)  126 (26.0)   
Black Other 22 (4.5)  22 (4.5)   
Asian 72 (14.9)  72 (14.9)   
Mixed 44 (9.1)  44 (9.1)   
Other 15 (3.1)  15 (3.1)   
Family history of 
psychosis  
120.6 (24.7)  120 (24.8)  2 (0.4) 




Pooled Original  
N (%) M (SD) N (%) M (Min-Max; SD) N of missing 
cases (%) 
Good 345.9 (71.5) 
 
345 (71.3)   





46.8 (8-90; 20.09) 13 (2.7) 
























71.32 (30-149; 24.25) 0 




23.07 (6.06-35.63; 5) 39 (8.1) 
Any substance 
abuse/ dependence 
in past 6 months 
159.3 (32.9)  133 (27.5)  75 (15.5) 
Employed/ student  177.8 (36.7)  168 (34.7)  28 (5.8) 
Long DUP (>=3 
months) 
252.9 (52.3)  222 (45.9)  63 (13) 
Note. M = mean, SD = standard deviation, N = number of patients, DUP = duration of untreated psychosis, GAF = 
Global Assessment of Functioning scale, GAF-d = disability subscale, GAF-s = symptom subscale, PANSS = 
Positive and Negative Syndrome Scale, PANSS-P = positive subscale, PANSS-N = negative subscale, PANSS-G = 






















Table 2. Multiple linear regression results for the predictor variables of PANSS-N scores at baseline  
Predictor baseline variables B SE B 95% CI for B t 
Team .16 .21 -.25 – .58 .76 
Gender -1.63 .70 -3.00 – -.26 -2.33* 
Age of Onset -.15 .07 -.29 – -.01 -2.10* 
Ethnicitya     
White Other  -.14 1.21 -2.51 – 2.23 -.12 
Mixed 2.14 1.32 -.44 – 4.72 1.63 
Asian -.25 1.15 -2.50 – 2.01 -.21 
Black Caribbean 1.67 1.29 -.85 – 4.19 1.30 
Black African 1.38 .99 -.54 – 3.32 1.41 
Black Other  1.60 1.70 -1.73 – 4.93 .94 
Other  3.13 2.00 -.80 – 7.06 1.56 
Family history of psychosis .012 .77 -1.49 – 1.52 .02 
Social supportb     
Limited  -1.11 .89 -2.85 – .63 -1.25 
None .88 1.42 -1.91 – 3.67 .62 
Employed/Student  -1.76 .72 -3.17 – .35 -2.45* 
Dichotomised DUP  .14 .70 -1.24 – 1.52 .20 
GAF-s .003 .03 -.05 –.06 .10 
GAF-d  -.19 .03 -.24 – - .13 -6.42*** 
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Predictor baseline variables B SE B 95% CI for B t 
Substance abuse in the past 6 months -3.05 .78 -4.58 – -1.52 -3.91*** 
Note. B = unstandardized regression coefficient, SE = standard error, R2 = proportion of the variance explained, 
F = F-ratio, t = t-test, CI = confidence intervals, GAF = Global Assessment of Functioning scale, GAF-d = 
disability subscale, GAF-s = symptom subscale, PANSS-N = Positive and Negative Syndrome Scale – negative 
subscale score, df = degrees of freedom, DUP = duration of untreated psychosis (DUP was dichotomized at 3 
months). 
a All ethnic groups were compared to White British; b Level of support were compared to Good Level  
Model R2= .31; Model Adjusted R2= .28; F(df)= 12.75 (462), p < .001 
Model’s constant, B= 28.38; B SE= 3.09; t= 9.18; p<.001; 95% CI 22.32 – 34.45. 
The model was controlled for PANSS Depression factor and PANSS positive subscale score. 




Table 3. Summary of linear regressions examining the effect of the level of baseline negative symptoms on 










F (df1, df2) t 
GAF-s -.28 (.10) -.49 – -.08 .02 .57 2.16 24.48 (15, 277)*** -2.70** 
GAF-d -.27 (.11) -.48– -.06 .02 .49 2.01 17.90 (15, 277)*** -2.57* 
Note. B = unstandardized regression coefficient, SE = standard error, R2 = proportion of the variance 
explained, Durbin Watson d = test statistic of autocorrelation, F = F-ratio, t = t-test, CI = confidence 
intervals, GAF = Global Assessment of Functioning scale, GAF-d = disability subscale, GAF-s = symptom 
subscale, df1 = regression degrees of freedom, df2 = residual degrees of freedom. 
a adjusted for team, age at psychosis onset, ethnicity, family history of psychosis, social support at baseline, 
employed/student at baseline, dichotomized duration of untreated psychosis, Positive and Negative 
Syndrome Scale (PANSS) depression factor at baseline, PANSS positive subscale score at baseline, 












F (df1, df2) t 
abuse or dependence in the 6 months prior to baseline. 









Table 4. Summary of binary logistic regressions examining the effect of the level of baseline negative 
symptoms on categorical outcome variables at 1-year follow-up. 






OR (95% CI) 
Adjusted a 
OR (95% CI) 
Remission  -.01 (.02) .40 .99 (.96 -1.01) .99 (.96-1.03) 
Positive Symptom 
Remission 
.02 (.02) 1.18 1.00 (97 -1.02) 1.02 (.98- 1.06) 
Admitted to a 
psychiatric ward  
.06 (.02) 11.09 1.06 (1.03 -1.08)*** 1.06 (1.02-1.10)** 
Used HTT or Crisis 
team 
.001 (.02) .11 1.00 (.97-1.02) 1.00 (.96-1.04) 
28 
 






OR (95% CI) 
Adjusted a 
OR (95% CI) 
Any suicide attempts -.004 (.05) .26 .98 (.94-1.04) 1.00 (.90-1.10) 
Any violent incident 
towards others 
.01 (.03) .25 1.01 (.98-1.04) 1.01 (.96-1.06) 
Note. PANSS = Positive and Negative Syndrome Scale, HTT = Home Treatment Team, OR = odds ratio, B 
= regression coefficient on the independent variable, CI = confidence interval. 
 a adjusted for team, age at psychosis onset, ethnicity, family history of psychosis, social support at baseline, 
employed/student at baseline, duration of untreated psychosis median split (<3 is short, > or =3 months is 
long), PANSS-D (depression subscale) at baseline, PANSS-P (positive subscale) at baseline, remission at 
baseline, diagnosis at 1-year follow-up, treatment adherence at 1-year follow-up, any substance abuse or 
dependence in the 6 months prior to baseline. 
* p < .05, **p < .01, ***p < .001. 
 
 
 
 
 
